CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
MT-1186 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04493281
NCT04493281Phase 1Completed
CompareCT.gov

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Tanabe Pharma Corporation·interventional·Posted Jul 30, 2020·Updated Jan 7, 2026

In Brief

A Phase 1 clinical trial evaluating MT-1186 and MCI-186 for Healthy Adult Subjects. Completed, enrolled 42 participants across 1 site.

Detailed Summary

To evaluate the single-dose bioequivalence of oral suspension and intravenous (IV) formulation of edaravone in the fasting state in healthy adult subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adult Subjects
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 30, 2020
Enrollment StartMar 22, 2019
Primary CompletionApr 21, 2019
Study CompletionMay 9, 2019
TodayJul 2, 2026
Enrollment to primary: 29 daysPosted 5.9 years ago

Interventions

MT-1186drug

Oral suspension

MCI-186drug

Intravenous formulation